Variable | ECOG 2 group | ECOG 0–1 group |  | pb | |||
---|---|---|---|---|---|---|---|
EP arm (n = 31) | PC arm (n = 40) | pa | EP arm (n = 64) | PC arm (n = 56) | pa | ||
Radiotherapy | |||||||
 Radiotherapy |  |  | 0.747 |  |  | 0.268 | 0.113 |
  ≥ 60 Gy | 25 (80.6%) | 31 (77.5%) |  | 54 (84.4%) | 51 (91.1%) |  |  |
  < 60 Gy | 6 (19.4%) | 9 (22.5%) |  | 10 (15.6%) | 5 (8.9%) |  |  |
 GTV (cm3) c | 98.0 (27.3–383.3) | 123.1 (56.4–298.6) | 0.859 | 123.9 (20.6—307.7) | 111.1 (8.6–485.4) | 0.809 | 0.797 |
 Mean lung dose (cGy) c | 1591 (900–1891) | 1550 (970–2004) | 0.657 | 1576 (957–2100) | 1588 (969–1895) | 0.531 | 0.908 |
 V20 of the both lungs (%) c | 26 (20–32) | 27 (13–35) | 0.292 | 27 (14–35) | 25.5 (14–31) | 0.127 | 0.176 |
 Reason for radiotherapy discontinuation | |||||||
  Unacceptable toxicity | 0 | 1 |  | 1 | 0 |  |  |
  Comorbidity | 0 | 0 |  | 0 | 0 |  |  |
  Patients request | 1 | 0 |  | 0 | 1 |  |  |
Chemotherapy | Â | Â | Â | Â | Â | Â | Â |
 Concurrent chemotherapy |  |  | 0.004 |  |  | 0.011 | 0.788 |
  EP = 2 cycles or PC ≥ 5 weeks | 28 (90.3%) | 24 (60.0%) |  | 54 (84.4%) | 36 (64.3%) |  |  |
  EP < 2 cycles or PC < 5 weeks | 3 (9.7%) | 16 (40.0%) |  | 10 (15.6%) | 20 (35.7%) |  |  |
 Reason for concurrent chemotherapy discontinuation | |||||||
  Unacceptable toxicity | 2 | 13 |  | 10 | 19 |  |  |
  Comorbidity | 0 | 1 |  | 0 | 0 |  |  |
  Patients request | 1 | 2 |  | 0 | 1 |  |  |
 Consolidation Chemotherapy |  |  | 0.594 |  |  | 0.080 | < 0.001 |
  Yes | 7 (22.6%) | 7 (17.5%) |  | 41 (64.1%) | 27 (48.2%) |  |  |
  No | 24 (77.4%) | 33 (82.5%) |  | 23 (35.9%) | 29 (51.8%) |  |  |